The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 27876250 |
60 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH |
Jagiellonian University Medical College |
| 27839919 |
192 |
Decahydrobenzoquinolin-5-one sigma receptor ligands: Divergent development of both sigma 1 and sigma 2 receptor selective examples. |
University Of Kansas |
| 27132867 |
154 |
Structure-guided development of dualß2 adrenergic/dopamine D2 receptor agonists. |
Friedrich-Alexander University |
| 26988801 |
55 |
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents. |
Jagiellonian University Medical College |
| 26704965 |
229 |
Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. |
University Of Illinois At Chicago |
| 26709102 |
142 |
Discovery of Vibegron: A Potent and Selectiveß3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder. |
Merck Research Laboratories |
| 26471092 |
23 |
Molecular hybridization yields triazole bronchodilators for the treatment of COPD. |
Pfizer |
| 26125514 |
40 |
Discovery of Novel Indazole Derivatives as Highly Potent and Selective Humanß3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects. |
Asahi Kasei Pharma |
| 25695425 |
62 |
Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors. |
City University Of New York |
| 25629394 |
52 |
Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist.. |
Theravance Biopharma |
| 25065493 |
92 |
The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-actingß2-adrenoceptor agonist. |
Novartis Institutes For Biomedical Research |
| 24881566 |
140 |
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). |
Glaxosmithkline |
| 25241924 |
47 |
The design and implementation of a generic lipopeptide scanning platform to enable the identification of 'locally acting' agonists for the apelin receptor. |
Novartis Institutes For Biomedical Research |
| 24835980 |
98 |
Discovery of TD-4306, a long-actingß2-agonist for the treatment of asthma and COPD. |
Theravance |
| 24878222 |
50 |
Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors. |
Pfizer |
| 24813741 |
110 |
Multivalent design of long-actingß(2)-adrenoceptor agonists incorporating biarylamines. |
Theravance |
| 24900851 |
6 |
Discovery of AZD3199, An Inhaled Ultralong Acting?2 Receptor Agonist with Rapid Onset of Action. |
Astrazeneca |
| 16640337 |
47 |
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists. |
Glaxosmithkline |
| 23614528 |
121 |
Synthesis and in vitro and in vivo characterization of highlyß1-selectiveß-adrenoceptor partial agonists. |
University Of Nottingham |
| 21870877 |
119 |
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for humanß-adrenoceptors. |
University Of Nottingham |
| 11806709 |
63 |
Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres. |
Glaxosmithkline |
| 22932315 |
28 |
An investigation into the structure-activity relationships associated with the systematic modification of theß(2)-adrenoceptor agonist indacaterol. |
Novartis Institutes For Biomedical Research |
| 22079756 |
219 |
From libraries to candidate: the discovery of new ultra long-acting dibasicß2-adrenoceptor agonists. |
Astrazeneca |
| 22178551 |
46 |
A multivalent approach to the discovery of long-actingß(2)-adrenoceptor agonists for the treatment of asthma and COPD. |
Theravance |
| 21925889 |
48 |
The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating a urea group. |
Glaxosmithkline |
| 21696967 |
51 |
The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating hydantoin or uracil rings. |
Glaxosmithkline |
| 21723724 |
91 |
Design-driven LO: the discovery of new ultra long acting dibasicß2-adrenoceptor agonists. |
Astrazeneca |
| 21652207 |
17 |
Design driven HtL: The discovery and synthesis of new high efficacyß2-agonists. |
Astrazeneca |
| 20462258 |
50 |
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. |
Glaxosmithkline |
| 19317397 |
62 |
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups. |
Glaxosmithkline |
| 19146417 |
70 |
The discovery of a selective, small molecule agonist for the MAS-related gene X1 receptor. |
Glaxosmithkline |
| 18433113 |
124 |
Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists. |
Glaxosmithkline |
| 9548813 |
53 |
The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. |
Smithkline Beecham Pharmaceuticals |
| 21486038 |
177 |
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. |
H. Lundbeck |
| 23641311 |
38 |
From a4ß2 Nicotinic Ligands to the Discovery of s1 Receptor Ligands: Pharmacophore Analysis and Rational Design. |
TBA |
| 22563707 |
27 |
A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design. |
Radboud University Nijmegen Medical Centre |
| 22313227 |
78 |
Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype. |
National Institute Of Mental Health |
| 24900353 |
6 |
Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity. |
TBA |
| 21207959 |
69 |
Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging. |
National Institute Of Mental Health |
| 20875743 |
90 |
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity rela |
Pfizer |
| 20684563 |
176 |
Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. |
H. Lundbeck |
| 20181479 |
177 |
Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles. |
Merck Research Laboratories |
| 19963380 |
38 |
Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. |
Hunter College And The Graduate Center Of The City University Of New York |
| 19821575 |
47 |
Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues. |
Glaxosmithkline |
| 19608416 |
29 |
Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6. |
Astellas Pharma |
| 19168263 |
14 |
Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist. |
Instituto Polit£Cnico Nacional (Ipn) |
| 19581100 |
162 |
Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists. |
Astellas Pharma |
| 19232786 |
72 |
Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists. |
Astellas Pharma |
| 18651730 |
123 |
Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety. |
Astellas Pharma |
| 18307290 |
97 |
Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I. |
Astellas Pharma |
| 17897826 |
18 |
The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD. |
Pfizer |
| 17498952 |
4 |
The discovery of long acting beta2-adrenoreceptor agonists. |
Pfizer |
| 16451077 |
86 |
Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists. |
Pfizer |
| 16198561 |
99 |
Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis. |
Novartis Institutes For Biomedical Research |
| 16220969 |
219 |
Designed multiple ligands. An emerging drug discovery paradigm. |
Organon Laboratories |
| 15603933 |
28 |
Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist. |
Fujisawa Pharmaceutical |
| 15482914 |
25 |
Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750. |
Pfizer |
| 15324892 |
9 |
Long-chain formoterol analogues: an investigation into the effect of increasing amino-substituent chain length on the beta2-adrenoceptor activity. |
Novartis Horsham Research Centre |
| 12213075 |
70 |
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). |
Purdue University |
| 11311069 |
64 |
(4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. |
Wyeth-Ayerst Research |
| 8691440 |
22 |
Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic. |
University Of Pennsylvania |
| 7658429 |
31 |
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431). |
Abbott Laboratories |
| 15203136 |
39 |
(+/-)8-Amino-5,6,7,8-tetrahydroisoquinolines as novel antinociceptive agents. |
Virginia Commonwealth University |
| 22182578 |
13 |
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the humanß2-adrenoceptor. |
Instituto Polit£Cnico Nacional (Ipn) |
| 21863888 |
9 |
Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-ß2-agonist for the treatment of chronic obstructive pulmonary disease. |
Pfizer |
| 21783363 |
10 |
Synthesis and in vitro evaluation of derivatives of theß¿?-adrenergic receptor antagonist HX-CH 44. |
University Of Toronto |
| 21591752 |
41 |
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. |
Soochow University College Of Pharmaceutical Sciences |
| 20036561 |
39 |
Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists. |
Medical University Of Lublin |
| 21615150 |
14 |
Progress in structure based drug design for G protein-coupled receptors. |
Heptares Therapeutics |
| 21075627 |
26 |
Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD. |
Pfizer |
| 21353541 |
25 |
Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective humanß3 adrenergic receptor agonists. |
Merck Research Laboratories |
| 21310610 |
63 |
Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules. |
Theravance |
| 24900301 |
24 |
Discovery of a Potent and Short−Acting Oral Calcilytic with a Pulsatile Secretion of Parathyroid Hormone |
TBA |
| 20833036 |
221 |
Thienopyrimidines asß3-adrenoceptor agonists: hit-to-lead optimization. |
4Sc |
| 20813948 |
63 |
Spiroindolones, a potent compound class for the treatment of malaria. |
Swiss Tropical And Public Health Institute |
| 20804199 |
23 |
Inhalation by design: novel ultra-long-actingß(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. |
Pfizer |
| 20655218 |
72 |
A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators. |
Novartis Institutes For Biomedical Research |
| 20620058 |
41 |
Smoothened antagonists for hair inhibition. |
Pfizer |
| 20591666 |
66 |
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase. |
Università |
| 20434333 |
111 |
A vHTS approach for the identification of beta-adrenoceptor ligands. |
4Sc |
| 20402514 |
34 |
The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
Novartis Institutes For Biomedical Research |
| 20384344 |
42 |
Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice. |
Meiji Seika Kaisha |
| 20096576 |
41 |
Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. |
Boehringer Ingelheim Pharma |
| 19857969 |
6 |
Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines. |
National Institute Of Diabetes And Digestive And Kidney Diseases |
| 19646882 |
72 |
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways. |
University Of Medicine And Dentistry Of New Jersey-Robert Wood Johnson Medical School And The Informatics Institute Of Umdnj |
| 19646865 |
45 |
Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence. |
Pfizer |
| 19643607 |
26 |
Studies towards topical selective beta2-adrenoceptor agonists with a long duration of action. |
Boehringer Ingelheim Pharma |
| 19875286 |
44 |
Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists. |
Boehringer Ingelheim Pharma |
| | 38 |
Carboxyl-promoted enhancement of selectivity for the β3 adrenergic receptor. Negative charge of the sulfonic acid BMS-187413 introduces-β3 binding selectivity |
TBA |
| | 26 |
BMS-187257, a potent, selective, and novel heterocyclic β3 adrenergic receptor agonist |
TBA |
| 19492813 |
56 |
Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues. |
Glaxosmithkline |
| 19366244 |
138 |
Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5. |
Astellas Pharma |
| 19362005 |
74 |
Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists. |
Astellas Pharma |
| 19081260 |
10 |
Substituted 1,2,3,4-tetrahydroquinolin-6-yloxypropanes as beta3-adrenergic receptor agonists: design, synthesis, biological evaluation and pharmacophore modeling. |
Central Drug Research Institute |
| 18829308 |
5 |
Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. |
Lundbeck Research Usa |
| 18656910 |
2 |
Facile radiosynthesis of fluorine-18 labeled beta-blockers. Synthesis, radiolabeling, and ex vivo biodistribution of [18F]-(2S and 2R)-1-(1-fluoropropan-2-ylamino)-3-(m-tolyloxy)propan-2-ol. |
Centre For Addiction And Mental Health |
| 18573659 |
47 |
Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides. |
Glaxosmithkline |
| 18553954 |
126 |
Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II. |
Astellas Pharma |
| 18507369 |
85 |
Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide. |
Theravance |
| 18180157 |
10 |
Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains. |
St. Jude Children'S Research Hospital |
| 17911024 |
37 |
Potent oxindole based human beta3 adrenergic receptor agonists. |
Eli Lilly |
| 17804228 |
44 |
Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists. |
Eli Lilly |
| 17632003 |
55 |
Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity. |
Pfizer |
| 17571866 |
49 |
Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography. |
National Institute Of Mental Health |
| 17533126 |
78 |
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 17524641 |
69 |
3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists. |
Glaxosmithkline |
| 17506540 |
52 |
Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. |
Medical University Of Lublin |
| 17303428 |
22 |
Novel chiral isoxazole derivatives: synthesis and pharmacological characterization at human beta-adrenergic receptor subtypes. |
Università |
| 16931005 |
21 |
Potent benzimidazolone based human beta(3)-adrenergic receptor agonists. |
Eli Lilly |
| 16722631 |
87 |
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. |
Predix Pharmaceuticals |
| 16392798 |
46 |
Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand. |
Columbia University College Of Physicians And Surgeons |
| 15686912 |
35 |
Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety. |
Dainippon Pharmaceutical |
| 15546708 |
35 |
Tryptamine-based human beta3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives. |
Dainippon Pharmaceutical |
| 15546707 |
60 |
Tryptamine-based human beta3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring. |
Dainippon Pharmaceutical |
| 14643338 |
124 |
Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
Virginia Commonwealth University |
| 12798332 |
35 |
Cyclic amine sulfonamides as linkers in the design and synthesis of novel human beta(3) adrenergic receptor agonists. |
Wyeth Research |
| 12657269 |
52 |
Novel and potent human and rat beta3-adrenergic receptor agonists containing substituted 3-indolylalkylamines. |
Dainippon Pharmaceutical |
| 12361399 |
17 |
Homoazanicotine: a structure-affinity study for nicotinic acetylcholine (nACh) receptor binding. |
Universita Di Camerino |
| 12270184 |
34 |
Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 2: arylethanolaminomethylpiperidines. |
Wyeth Research |
| 12270183 |
45 |
Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 1: aryloxypropanolaminomethylpiperidines. |
Wyeth Research |
| 11327605 |
27 |
New oxadiazolidinedione derivatives as potent and selective human beta3 agonists. |
Wyeth-Ayerst Research |
| 11277513 |
25 |
2,4-Thiazolidinediones as potent and selective human beta3 agonists. |
Wyeth-Ayerst Research |
| 11212115 |
72 |
Human beta3 adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties. |
Merck Research Laboratories |
| 11055339 |
59 |
Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human beta3 adrenergic receptor agonists. |
Merck Research Laboratories |
| 11052788 |
33 |
Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide. |
Merck Research Laboratories |
| 10999482 |
52 |
Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides. |
Merck Research Laboratories |
| 10987429 |
69 |
Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore. |
Merck Research Laboratories |
| 10915043 |
69 |
Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists. |
Merck Research Laboratories |
| 10888325 |
90 |
Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents. |
Merck Research Laboratories |
| 10888324 |
48 |
Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist. |
Merck Research Laboratories |
| 10406657 |
91 |
Potent, elective human beta3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore. |
Merck Research Laboratories |
| 10360736 |
2 |
S1319: a novel beta2-andrenoceptor agonist from a marine sponge Dysidea sp. |
Kirin Brewery |
| 10340609 |
15 |
L-770,644: a potent and selective human beta3 adrenergic receptor agonist with improved oral bioavailability. |
Merck Research Laboratories |
| 10201842 |
69 |
Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides. |
Merck Research Laboratories |
| 10201841 |
47 |
Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides. |
Merck Research Laboratories |
| 9873681 |
65 |
3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists. |
Merck Research Laboratories |
| 9873496 |
80 |
3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties. |
Merck Research Laboratories |
| 9871717 |
72 |
Discovery of L-755,507: a subnanomolar human beta 3 adrenergic receptor agonist. |
Merck Research Laboratories |
| 9871716 |
94 |
Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor. |
Merck Research Laboratories |
| 9379432 |
36 |
Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign pr |
Abbott Laboratories |
| 1648138 |
33 |
Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. |
Universitá |
| 27214403 |
37 |
Structural analysis of human KDM5B guides histone demethylase inhibitor development. |
University Of Oxford |
| 26833890 |
18 |
Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease. |
Yogi Vemana University |
| 27128689 |
28 |
Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2. |
National Institutes Of Health |
| 26469307 |
7 |
Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b. |
University Of Leipzig |
| 2172674 |
5 |
Amplification of the rat M2 muscarinic receptor gene by the polymerase chain reaction: functional expression of the M2 muscarinic receptor. |
University Of Arizona |
| 1831904 |
27 |
Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. |
Duke University |
| 15725032 |
3 |
Development of a technique to determine bicyclomycin-rho binding and stoichiometry by isothermal titration calorimetry and mass spectrometry. |
University Of North Carolina |
Search and Browse
